What did @smallersam_pcos actually say?
Here's the uncomfortable truth: the creator didn't say much of anything in the actual video. The transcript is essentially a string of filler words: "Okay. Okay. Okay. So we're gonna go back and forth a little bit." That's it. The substantive claims, including the dosage figures and the WeightCare promotion, appear entirely in the caption, not in spoken content.
The caption states they reached a peak dose of "80 units weekly" of semaglutide and are now maintaining on "20 units weekly." They also promote WeightCare using affiliate discount codes, and the video is tagged as a sponsored partnership. Viewers watching the video without reading the caption may not even receive the core claims being fact-checked here. That's worth naming plainly.
Does the science back this up?
The dosing language here is a red flag, and the research doesn't make it easier to evaluate. Semaglutide doses are typically expressed in milligrams, not units. Ozempic and Wegovy are dosed at 0.25 mg up to 2.4 mg weekly. Compounded semaglutide preparations, which are what telehealth platforms like WeightCare likely dispense, are sometimes drawn from vials and measured in units on an insulin syringe, meaning the "units" figure depends entirely on the concentration of the specific compounded product.
Without knowing the concentration, "80 units" is clinically meaningless to the public. A 2021 NEJM trial by Wilding et al. established that 2.4 mg weekly semaglutide produced roughly 15% body weight reduction over 68 weeks in adults with obesity. Dose-response relationships matter, and presenting unit-based dosing to a lay audience without concentration context is genuinely misleading, even if unintentionally so.
What did they get wrong (or right)?
The creator gets partial credit for acknowledging a dose reduction over time, which aligns with how clinicians actually use GLP-1 agonists for maintenance. Research by Davies et al. (2021, Diabetes Care) supports the idea that lower maintenance doses may be appropriate once target weight is reached. That part is not wrong.
What is wrong, or at least irresponsible, is presenting raw unit figures to 309,000 viewers without any concentration context. Someone seeing "80 units weekly" might attempt to replicate that on a compounded product with a different concentration and end up taking a dangerously different actual dose. The American Society of Health-System Pharmacists has flagged exactly this kind of concentration confusion as a patient safety concern with compounded semaglutide. The caption also functions as a paid promotion while being framed as personal experience, which the FTC requires to be disclosed clearly. The #weightcarepartner tag does appear, so disclosure exists, but the line between testimonial and medical guidance blurs fast at this scale.
What should you actually know?
If you're considering semaglutide through any telehealth platform, a few things matter more than what a TikTok creator took. First, compounded semaglutide is not FDA-approved and is not equivalent to Wegovy or Ozempic. The FDA has stated explicitly that compounded drugs do not undergo the same safety and efficacy review. Second, dosing must be determined by a licensed prescriber based on your specific health history, not by reverse-engineering a caption.
Third, PCOS is tagged in this video, and that context matters clinically. A 2022 meta-analysis by Joham et al. in Lancet Diabetes and Endocrinology found that GLP-1 receptor agonists may improve metabolic markers in people with PCOS, but evidence for semaglutide specifically in this population is still limited. Using creator content as a treatment guide for a complex hormonal condition is not a substitute for individualized medical care.
- Never adjust your semaglutide dose based on unit figures from social media without confirming your product's concentration with your prescriber.
- Compounded semaglutide and brand-name semaglutide are not the same product legally or regulatorily.
- Affiliate codes and transformation content can coexist with genuine experience, but that doesn't make the dosing information clinically safe to replicate.